PathAI, a global provider of artificial intelligence-powered technology for pathology, announced today the closing of its $165 million Series C financing. PathAI will deploy its new capital to accelerate product development while continuing to prioritize the improvement of patient outcomes with reliable AI-powered technology and meaningful collaboration with pharmaceutical and diagnostic partners.

PathAI is a leading provider of AI-powered technology for pathology. PathAI's platform promises substantial improvements to the accuracy of diagnosis and the efficacy of treatment of diseases like cancer, leveraging modern approaches in machine and deep learning. Based in Boston, PathAI works with leading life sciences companies and researchers to advance precision medicine. To learn more, visit pathai.com.

Pathai Announces Completion Of $165 Million Financing For Advancing Medicine With Ai-Powered Pathology

Description

Company Information

Pathai Announces Completion Of $165 Million Financing For Advancing Medicine With Ai-Powered Pathology

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Company Information